RenovoRx Inc
RNXT1.225USD
+0.015+1.24%
取引時間 （ET）15分遅れの株価
44.77M時価総額
損失額直近12ヶ月PER
詳細情報 RenovoRx Inc 企業名
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
企業情報
企業コードRNXT
会社名RenovoRx Inc
上場日Aug 17, 2021
最高経営責任者「CEO」Mr. Shaun R. Bagai
従業員数10
証券種類Ordinary Share
決算期末Aug 17
本社所在地2570 W. El Camino Real, Ste. 320,
都市MOUNTAIN VIEW
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号94040
電話番号14088002649
ウェブサイトhttps://renovorx.com/
企業コードRNXT
上場日Aug 17, 2021
最高経営責任者「CEO」Mr. Shaun R. Bagai
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Ronald B. (Ron) Kocak, CPA
Mr. Ronald B. (Ron) Kocak, CPA
Principal Financial Officer and Accounting Officer, Vice President, Controller
Principal Financial Officer and Accounting Officer, Vice President, Controller
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, May 17
更新時刻: Sat, May 17
株主統計
種類
株主統計
株主統計
比率
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
株主統計
株主統計
比率
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
種類
株主統計
比率
Investment Advisor/Hedge Fund
10.42%
Private Equity
7.09%
Investment Advisor
5.92%
Individual Investor
4.42%
Hedge Fund
3.79%
Bank and Trust
0.27%
Venture Capital
0.06%
Other
68.03%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
51
11.69M
31.97%
+5.32M
2025Q1
52
10.53M
29.46%
+6.73M
2024Q4
39
1.47M
4.14%
-2.25M
2024Q3
38
2.35M
9.16%
-392.19K
2024Q2
40
2.34M
14.23%
-1.80M
2024Q1
36
1.98M
17.38%
-1.99M
2023Q4
40
1.81M
16.91%
-1.93M
2023Q3
39
3.15M
32.01%
-2.10M
2023Q2
36
3.04M
31.03%
-2.11M
2023Q1
36
5.01M
55.46%
+3.39M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
AIGH Capital Management, LLC.
2.59M
7.09%
+2.59M
--
Mar 31, 2025
AWM Investment Company, Inc.
2.29M
6.25%
+2.29M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.35M
3.68%
+1.20M
+851.09%
Mar 31, 2025
Agah (Ramtin M.D.)
1.13M
3.1%
+21.00K
+1.89%
Jun 05, 2025
Worth Venture Partners, LLC
873.61K
2.39%
+873.61K
--
Mar 31, 2025
Alyeska Investment Group, L.P.
688.58K
1.88%
+688.58K
--
Mar 31, 2025
Bleichroeder LP
500.00K
1.37%
+500.00K
--
Mar 31, 2025
Adar1 Capital Management LLC
479.88K
1.31%
+282.63K
+143.29%
Mar 31, 2025
Geode Capital Management, L.L.C.
321.87K
0.88%
+86.13K
+36.53%
Mar 31, 2025
Bagai (Shaun R.)
320.04K
0.88%
+27.50K
+9.40%
Apr 25, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
